Results 211 to 220 of about 823,617 (410)
Demystifying the gender of patient after allogeneic bone marrow transplantation from an opposite-sex donor: A case report. [PDF]
Teng J +8 more
europepmc +1 more source
Non‐endocrine late complications of bone marrow transplantation in childhood: part II [PDF]
Alison Leiper
openalex +1 more source
CXCR4 functions as a potential cancer stem cell‐associated marker linked to chemoresistance in ovarian cancer, and an inhibitor of CXCR4, AMD3100, can enhance the cytotoxic response to cisplatin. Based on these findings, [68Ga]Ga‐Pentixafor positron emission tomography enables selective visualization of CXCR4‐high ovarian cancer, while AMD3100 combined
Lixia Feng +12 more
wiley +1 more source
Antibiotic Resistance to <i>Pseudomonas Aeruginosa</i> in the Saliva of Candidates of Bone Marrow Transplantation. [PDF]
Zahed M +4 more
europepmc +1 more source
Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo +5 more
wiley +1 more source
Daratumumab-induced acute angle closure glaucoma: bone marrow transplantation as a possible risk factor and atropinization as a potential solution. [PDF]
Yuksel Elgin C +3 more
europepmc +1 more source
Multilineage hematopoietic reconstitution of supralethally irradiated rats by syngeneic whole organ transplantation: with particular reference to the liver [PDF]
Demetris, AJ +6 more
core
Plasticity changes of molecular networks form a cellular learning process. Signaling network plasticity promotes cancer, metastasis, and drug resistance development. 55 plasticity‐related cancer drug targets are listed (20 having already approved drugs, 9 investigational drugs, and 26 being drug target candidates).
Márk Kerestély +5 more
wiley +1 more source

